Artificial Insemination Market by Type (Insemination Kits, Home, Conception Devices, and Accessories), by Procedure (Intrauterine Insemination, Intracervical Insemination, Intravaginal Insemination, and Intratubal Insemination), by Source Type (AIH-Husband and AID-Donor), by End-User by Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032

Report Overview

Artificial Insemination Market size is expected to be worth around USD 4,784 Mn by 2032 from USD 2,140 Mn in 2022, growing at a CAGR of 8.6% during the forecast period from 2023 to 2032.

Request Covid - 19 Impact

Artificial insemination, also known as artificial fertilization homologous (AIH), and artificial insemination recipient semen (AID), are all methods used for assisted reproduction where semen containing live sperm is introduced into a woman's cervix, fallopian tubes, or uterus. They may be done through short and painless artificial fertilization homologous treatments (AIH), or artificial insemination recipient semen (AID). On the market are now self-insemination kits that can be used at home.

Artificial insemination has the potential to improve reproductive success rates and save endangered or threatened species by increasing their viability during reproduction. Artificial insemination is also employed to prevent the spread of certain diseases or sterility among animals due to genital conditions. Genus' Plc, a leading animal genetics company, recently collaborated with Beijing Capital Agribusiness Co. Ltd on virus-resistant techniques for pigs.

Major pharmaceutical companies are investing in the development of drugs that have undergone clinical and preclinical testing, as well as introducing new insemination systems with proven benefits to spur market expansion. Artificial insemination is also becoming more popular due to rising infertility rates around the world.

Driving factors

The Rising Infertility Rates Are Driving the Global Artificial Insemination Marketplace Growth

Globally, infertility is on the rise among both individuals and couples. According to data from the National Institute of Health, 9% of men and 11% of women of procreative age in America have experienced fertility issues in recent years. According to the World Health Organization (WHO), 48 million couples and 180 million individuals worldwide experience infertility issues. While there are various treatments for infertility available such as artificial insemination, donor egg IVF service, and others, it's estimated that approximately 48 million couples worldwide struggle with it.

Individuals and couples can improve their chances of conception by using various treatments. Infertility is often caused by lifestyle changes, increased stress, and exposure to the environment - so infertility will continue to be a growing issue for couples and individuals in the near future, driving demand for assisted reproductive technologies like artificial insemination. These treatments have proven successful for many in the past; now, more people than ever before are turning to them for help.

The Increasing Alertness Among People About Reproductive Treatments Is Further Powering the Development Rate of the Artificial Insemination Market.

Recently, there has been an increased awareness of various reproductive techniques. Now more assisted reproductive technologies are accessible through various media outlets, including artificial reproduction. These procedures have become more popular due to increased visibility and accessibility of artificial insemination techniques as well as more infertility clinics, hospitals, and other facilities across the country.

The market for same-sex marriages is expected to grow due to increased government support in some countries and the inclusion of fertility treatment costs within insurance coverage in certain nations. Full-time women who work full-time often postpone having children until later in life, which can present unique challenges. Couples such as these may qualify for assisted reproductive treatments like artificial insemination, but even then, there can be obstacles to overcome. Artificial insemination is expected to become increasingly in demand as more women opt for planned parenthood. This trend can be attributed to technological advances in artificial insemination, rising disposable income levels, and an expanding network of fertility clinics and hospitals around the world.

Restraining Factors

Market Growth Is Hindered by The High Costs Associated with Assisted Reproductive Treatments Such as Artificial Insemination.

Due to their higher cost, these treatments are not accessible to a large number of people, and thus demand is lower. Market growth may also be hindered by ethical and religious concerns about artificial insemination in some regions around the world, as well as low awareness about assisted reproductive technology in those same countries. Furthermore, limited insurance coverage and strict regulatory environments will adversely impact market expansion.

By Procedure Analysis

By procedure in 2022, intrauterine insemination will hold the largest market share by type. Segmental growth will continue to be the dominant trend during this time; of all available treatments, intrauterine insemination remains the most successful and popular option available today. Intrauterine insemination (IUI) remains a popular choice due to the absence of surgery required.

The IUI segment will experience significant growth over the coming years due to an increasing fertility rate, improved technology adoption for IUI procedures, and greater public awareness about assisted reproductive technologies. Forecasts suggest the intravaginal segment will experience healthy growth over the coming years, accounting for the second-largest share of global artificial fertilization in 2021. IVI can be used for donor or surrogacy purposes and can be performed from home or at a fertility clinic.

By Source Type Analysis

According to a source, artificial insemination of husband (AIH) is expected to dominate the global market over the forecast period and boasts the highest compound annual growth rate (CAGR). This procedure requires the husband to collect semen for artificial insemination; it allows couples to establish biological connections without needing sperm donors and has seen rapid growth due to technological advancements in artificial insemination as well as changes in regulations and consumer preferences.

Artificial insemination through donors (AID) is expected to experience a healthy compound annual growth rate over the coming years due to an increasing number of single women and gay couples opting for this method of reproduction.

By End-User Analysis

Segmented by end-user of artificial insemination market, hospitals & clinics, fertility centers, and other end-users. Fertility clinics have adopted various strategies in order to raise customer awareness about treatments available for infertility issues due to an increasing global infertility rate. These factors will continue driving growth within this segment over the forecast period.

Key Market Segments

By Type

• Insemination Kits
• Home Conception Devices
• Accessories

By Procedure

• Intrauterine Insemination
• Intracervical Insemination
• Intravaginal Insemination
• Intratubal Insemination

By Source Type

• AIH-Husband
• AID-Donor

 By End-User

• Hospitals and Clinics
• Fertility Centers
• Other End-Users

Growth Opportunity

Insurance Companies That Cover Artificial Insemination Treatment Under Medical Coverage

Artificial insemination is now widely covered by many insurance companies as a medical procedure, helping patients fight infertility while creating opportunities for the insurance industry. Furthermore, international organizations and governments create policies to improve medical connectivity; according to UN Security Council, data 84% of countries support policies that directly or indirectly impact their infertility rates.

Latest Trends

One major factor driving this market is an increasing infertility rate and growing awareness about alternative reproductive methods. The market has also been affected by the legalization of gay marriages and providing insurance coverage for civil unions that permit artificial insemination. Artificial insemination is becoming more commonplace among domestic livestock due to the growing global population and rising demand for animal-based proteins.

Furthermore, this market is supported by rising animal healthcare expenditures and improved veterinary services. Top players in the market are entering into strategic partnerships to expand their animal genetic portfolio and enhance their presence across different markets. Genus plc, a highly ranked animal genetics company, recently joined forces with Beijing Capital Agribusiness Co. Ltd. to develop and test virus-resistant techniques for pigs.

Regional Analysis

North American Artificial Insemination Held a Large Share of the Global Artificial Insemination Market

North American artificial insemination accounted for a considerable share of the global artificial insemination market in 2022 due to its advanced technology and government support for fertility insurance. Assistive reproductive technology and infertility treatments such as artificial insemination are driving regional market expansion. In 2022, the European artificial insemination sector held a dominant share of the global artificial fertilization market. The European market is expected to post positive compound annual growth rates during the forecast period.

This expansion is being spurred by an increasing number of couples facing difficulties in reproduction. According to data released by the European Society for Human Reproduction and Embryology, 25 million European couples will experience infertility by 2025. The European artificial insemination market is expanding due to factors such as increasing demand for assisted reproductive technology and minimally invasive fertility treatment. To meet this growing need for artificial fertilization services, leading players in this sector are investing heavily in research and development (R&D).

Key Regions and Countries

North America

• US
• Canada
• Mexico

Western Europe

• Germany
• France
• The UK
• Spain
• Italy
• Portugal
• Ireland
• Austria
• Switzerland
• Benelux
• Nordic
• Rest of Western Europe

Eastern Europe

• Russia
• Poland
• The Czech Republic
• Greece
• Rest of Eastern Europe

APAC

• China
• Japan
• South Korea
• India
• Australia & New Zealand
• Indonesia
• Malaysia
• Philippines
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Colombia
• Chile
• Argentina
• Costa Rica
• Rest of Latin America

Middle East & Africa

• Algeria
• Egypt
• Israel
• Kuwait
• Nigeria
• Saudi Arabia
• South Africa
• Turkey
• United Arab Emirates
• Rest of MEA

Key Players Analysis

The market contains Tier-1, and Tier-2, & local players dominate the market. financial stability and strategic developments as well as a diversified regional presence, companies such as Rinovum Women's Health/Pride Angel, Vitrolife AB/Genea Limited, and Hi-tech Solutions/Kitazato Corporation dominate. They prioritize research and development while adopting strategic growth initiatives like product introductions, joint ventures, and partnerships in an effort to strengthen their position and gain a large customer base.

With the presence of many local and regional players, the market for artificial insemination is fragmented. Market players are subject to intense competition from top market players, particularly those with strong brand recognition and high distribution networks. To stay on top of the market, companies have gained various expansion strategies such as partnerships and product launches.

Top Key Players in Artificial Insemination Market

• Conceivex, Inc.
• Pride Angel
• FUJIFILM Irvine Scientific
• High-Tech Solutions
• Rinovum Women's Health, LLC
• TenderNeeds Fertility
• Biogenics Inc.
• LABOTECT GMBH
• Hamilton Thorne, Inc.
• Nikon Instruments Inc.
• Zander scientific Inc.
• Other Key Players.

Recent Development

In February 2023, China's National Healthcare Security Administration announced the costs of assisted reproductive technology in medical insurance. This is expected to encourage artificial insemination in China.
In August 2020, Cogent partnered up with AB Europe, a sheep-breeding company, in order to create a sexed service for British sheep producers.
In August 2019, Madras Veterinary College's Department of Veterinary, Gynecology, and Obstetrics started artificial insemination of cattle using sexed sperm.
In March 2018, JXTGE announced that Irvine Scientific will be sold to FUJIFILM in order to maximize synergies and to continue growing in the biomedical sector.

Report Scope: